On August 6, 2025 Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, reported that the Company generated revenue of $811 million for the second quarter ended June 30, 2025, compared to $699 million for the same period of 2024 (Press release, Exact Sciences, AUG 6, 2025, View Source [SID1234654863]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The Exact Sciences team continues to build momentum, advancing our mission through earlier detection," said Kevin Conroy, chairman and CEO. "In the second quarter, we delivered answers to more patients than ever driven by strong momentum behind the successful launch of Cologuard Plus, powerful commercial execution, and exceptional customer satisfaction. This progress strengthens our platform and enables us to deliver better outcomes for patients."

Second quarter 2025 financial results

For the three-month period ended June 30, 2025, as compared to the same period of 2024 (where applicable):

Total revenue was $811 million, an increase of 16% on a reported and core revenue basis
Screening revenue was $628 million, an increase of 18%
Precision Oncology revenue was $183 million, an increase of 9%
Gross margin was 69%, and adjusted gross margin was 72%
Net loss was $1 million, or $0.01 per share, an improvement of $15 million and $0.08 per share, respectively
Adjusted EBITDA was $138 million, an increase of $28 million or 26%, and adjusted EBITDA margin was 17%, an increase of 130 basis points
Operating cash flow was $89 million and free cash flow was $47 million,
Cash, cash equivalents, and marketable securities were $858 million at the end of the quarter
Screening primarily includes laboratory service revenue from Cologuard tests and PreventionGenetics. Precision Oncology includes laboratory service revenue from global Oncotype DX and therapy selection tests.

Platform and pipeline advancements

In April 2025, Exact Sciences launched the Oncodetect test, its molecular residual disease and recurrence monitoring test. Oncodetect identifies residual disease up to two years earlier than imaging, the current standard of care. The Company recently received Medicare coverage through the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program (MolDX) for serial use in patients with stage II, III and resectable stage IV colorectal cancer (CRC) in the adjuvant and recurrence monitoring settings over a five-year period.

In September 2025, Exact Sciences plans to launch its Cancerguard multi-cancer screening test as a laboratory-developed test. The Company plans to bring the test to patients through its large commercial organization and unique ExactNexus technology platform.

In August 2025, Exact Sciences acquired exclusive rights to the current and future versions of Freenome’s blood-based colorectal cancer screening tests as well as the underlying technology for colorectal cancer, subject to customary regulatory approvals. Additionally, the Company announced initial study results from the pivotal BLUE-C study for an internal version of its blood-based colorectal cancer screening test.

2025 outlook

The Company has updated its full-year 2025 revenue and adjusted EBITDA guidance:

Prior guidance

August 6 update

Change at midpoint

Y/Y growth rate

Total revenue

$3.070 – $3.120 billion

$3.130 – $3.170 billion

$55.0 million

14%

Screening

$2.390 – $2.425 billion

$2.440 – $2.470 billion

$47.5 million

17%

Precision Oncology

$680 – $695 million

$690 – $700 million

$7.5 million

6%

Adjusted EBITDA

$425 – $455 million

$455 – $475 million

$25.0 million

44%

Second-quarter 2025 conference call & webcast

Company management will host a conference call and webcast on Wednesday, August 6, 2025, at 5 p.m. ET to discuss second-quarter 2025 results. The webcast will be available at exactsciences.com. Domestic callers should dial 888-330-2384 and international callers should dial +1-240-789-2701. The access code for both domestic and international callers is 4437608. A replay of the webcast will be available at exactsciences.com. The webcast, conference call, and replay are open to all interested parties.